Launched in 2006, the Talecris New Trials Support (Talents) program is an initiative supporting investigator-initiated trials conceived by researchers and clinicians with an interest in intravenous immunoglobulin (IGIV) therapies. Each year, Talecris will pledge $1 million to fund basic science and clinical research projects in various fields, including immunology, hematology, and neurology. The Talents program has 3 key aims:
 

			Further the understanding of the efficacy and mechanisms of action of IGIV in current clinical indications
			Explore new clinical uses of IGIV
			Support the intellectual endeavors of the IGIV research community

As the name implies, the Talents program is seeking talented, capable researchers with innovative ideas and research projects that ultimately lead to improvements in patient care.

Learn more about the Talents program.


Partnership Fund

 


The Partnership Fund is a unique collaboration among Bayer Inc.'s, Bayer HealthCare Canada (the Biological Products Division), Talecris Biotherapeutics Inc., Héma-Québec and Canadian Blood Services. Under various names, this program has been in continuous operation since 1990 and has allocated millions of dollars in grants. The Partnership Fund's mission is to promote and support Canadian research and development into innovative blood products with the ultimate goal of improving patient care.

Funding decisions are made by a research-granting agency representing all four partners and funds are awarded according to scientific merit. For more information, visit the Partnership Fund Web site.